Skip to main content

Table 1 Demographics and disease characteristics

From: A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

  Pegfilgrastim 6 mg Filgrastim 5 μg/kg/day
No. of Patients 42 41
Age   
   Median (range), years 51 (18–74) 54 (19–79)
   < 55 years, n (%) 22 (52%) 21 (51%)
   ≥ 55 years, n (%) 20 (48%) 20 (49%)
Male, n (%) 22 (52%) 17 (41%)
Baseline ANC, × 109/L   
   Mean (SD) 2.2 (5.4) 2.3 (4.0)
   Median (range) 0.4 (0.0–33.8) 1.0 (0.0–17.4)
Most common FAB Type, n (%)   
   M1 9 (21%) 9 (22%)
   M2 8 (19%) 11 (27%)
   M4 12 (29%) 4 (10%)
   M4eo 3 (7%) 3 (7%)
   M5 4 (10%) 6 (15%)
Cytogenetics, n (%)   
   Intermediate 34 (81%) 38 (93%)
   Favorable 7 (17%) 3 (7%)
   Unfavorablea 1 (2%) 0 (0%)
Bone marrow cellularity, n (%)   
   Hypoplastic 4 (10%) 5 (12%)
   Normoplastic 4 (10%) 8 (20%)
   Hyperplastic 33 (79%) 28 (68%)
   Unknown 1 (2%) 0 (0%)
  1. ANC, absolute neutrophil count; SD, standard deviation; FAB, French American British.
  2. aCytogenetic classification re-evaluated after randomization; patient ineligible, but included in analyses consistent with intent-to-treat principles.